2021
Severity of Severe Acute Respiratory System Coronavirus 2 (SARS-CoV-2) Alpha Variant (B.1.1.7) in England
Grint DJ, Wing K, Houlihan C, Gibbs HP, Evans SJW, Williamson E, McDonald HI, Bhaskaran K, Evans D, Walker AJ, Hickman G, Nightingale E, Schultze A, Rentsch CT, Bates C, Cockburn J, Curtis HJ, Morton CE, Bacon S, Davy S, Wong AYS, Mehrkar A, Tomlinson L, Douglas IJ, Mathur R, MacKenna B, Ingelsby P, Croker R, Parry J, Hester F, Harper S, DeVito NJ, Hulme W, Tazare J, Smeeth L, Goldacre B, Eggo RM. Severity of Severe Acute Respiratory System Coronavirus 2 (SARS-CoV-2) Alpha Variant (B.1.1.7) in England. Clinical Infectious Diseases 2021, 75: e1120-e1127. PMID: 34487522, PMCID: PMC8522415, DOI: 10.1093/cid/ciab754.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 alpha variantHospital admissionAlpha variantWild-type virusCox proportional hazards regressionS gene target failureIntensive care unitProportional hazards regressionSARS-CoV-2Pathways of diseaseHigher hazardWild-type casesCause deathCause mortalityCare unitHazards regressionIndividual-level demographicsPrimary careCommunity testingInfection incidenceNHS EnglandDeath dataHigh transmissibilityAdmissionSeverityUse of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts
Wong AY, MacKenna B, Morton CE, Schultze A, Walker AJ, Bhaskaran K, Brown JP, Rentsch CT, Williamson E, Drysdale H, Croker R, Bacon S, Hulme W, Bates C, Curtis HJ, Mehrkar A, Evans D, Inglesby P, Cockburn J, McDonald HI, Tomlinson L, Mathur R, Wing K, Forbes H, Eggo RM, Parry J, Hester F, Harper S, Evans SJ, Smeeth L, Douglas IJ, Goldacre B, Collaborative T. Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts. Annals Of The Rheumatic Diseases 2021, 80: 943-951. PMID: 33478953, PMCID: PMC7823433, DOI: 10.1136/annrheumdis-2020-219517.Peer-Reviewed Original ResearchConceptsNon-steroidal anti-inflammatory drugsPrescribed non-steroidal anti-inflammatory drugsRheumatoid arthritis/osteoarthritisArthritis/osteoarthritisCurrent NSAID usersMultivariable-adjusted modelsAnti-inflammatory drugsNSAID prescriptionsNSAID usersGeneral populationCOVID-19Risk of deathNational Health Service EnglandRoutine therapeutic useRoutine clinical dataCohort studyCurrent useCox regressionClinical dataCohort analysisLower riskEvidence of differencesDeath dataTherapeutic useDeath
2020
Study protocol: Comparison of different risk prediction modelling approaches for COVID-19 related death using the OpenSAFELY platform
Williamson E, Tazare J, Bhaskaran K, Walker A, McDonald H, Tomlinson L, Bacon S, Bates C, Curtis H, Forbes H, Minassian C, Morton C, Nightingale E, Mehrkar A, Evans D, Nicholson B, Leon D, Inglesby P, MacKenna B, Cockburn J, Davies N, Hulme W, Morley J, Douglas I, Rentsch C, Mathur R, Wong A, Schultze A, Croker R, Parry J, Hester F, Harper S, Perera R, Grieve R, Harrison D, Steyerberg E, Eggo R, Diaz-Ordaz K, Keogh R, Evans S, Smeeth L, Goldacre B. Study protocol: Comparison of different risk prediction modelling approaches for COVID-19 related death using the OpenSAFELY platform. Wellcome Open Research 2020, 5: 243. DOI: 10.12688/wellcomeopenres.16353.1.Peer-Reviewed Original ResearchRisk prediction modelPrimary care electronic health record dataCOVID-19Chronic disease settingsElectronic health record dataHealth record dataPrevalence of infectionCOVID-19 deathsWorld Health OrganizationOpenSAFELY platformAdult patientsPoor outcomeInfection burdenDisease settingsDeath dataInfectious diseasesHealth OrganizationInfection prevalenceRecord dataCohort approachPopulation of interestPrevalenceTime-varying measuresDeathOutcomes